Daily intelligence on the peptide research industry.

Pharma & GLP-1

Novo Nordisk and Orbis Medicines Sign Up-to-$1.4 Billion Oral Macrocyclic Peptide Pact for Cardiometabolic Disease

Novo Nordisk has entered a discovery and licensing collaboration with Orbis Medicines worth up to $1.4 billion to develop oral macrocyclic peptides for cardiometabolic conditions currently dominated by injectable drugs. The deal, reported by Reuters on 17 September 2026, signals Novo's intent to extend its oral-drug ambitions beyond semaglutide into a structurally distinct molecule class.

18 Sep 2026

Pharma & GLP-1

Lilly's EASD 2026 Disclosures: TRIUMPH-2 Phase 3 Retatrutide Data, ACHIEVE-4 Foundayo Cardiovascular Findings, and a First Look at eloraTZP Phase 2

Eli Lilly published its pre-EASD data package on 15 September 2026, confirming Phase 3 TRIUMPH-2 results for the investigational triple agonist retatrutide, Phase 3 ACHIEVE-4 cardiovascular data for orforglipron (Foundayo), and a forthcoming Phase 2 readout for eloraTZP — a combination of eloralintide and tirzepatide. The disclosures arrive against a backdrop of active illicit-market enforcement, with a regulatory filing for retatrutide expected before year-end.

16 Sep 2026

Pharma & GLP-1

CagriSema: The Amylin–GLP-1 Combination With an FDA Decision Due in Q4 2026, a Mixed Trial Record, and No MHRA Pathway Announced

Novo Nordisk's CagriSema — a fixed-dose weekly injection combining semaglutide and the long-acting amylin analogue cagrilintide — is awaiting an FDA decision in the fourth quarter of 2026. The compound produced up to 22.7% weight loss in pivotal trials but failed to demonstrate non-inferiority against tirzepatide in a head-to-head study. No MHRA or EMA regulatory pathway has been announced for the UK or EU.

01 Sep 2026

Pharma & GLP-1

Foundayo (Orforglipron) Lands in UK Pharmacies: What the MHRA Approval and Private Launch Mean for the GLP-1 Landscape

Eli Lilly's oral GLP-1 receptor agonist orforglipron (Foundayo) launched in UK private pharmacies on 24 August 2026, three weeks after the MHRA became the first European regulator to authorise it. As a non-peptide small molecule — not a peptide drug — it represents a structurally distinct route to GLP-1 receptor activation with supply-chain implications that differ from conventional peptide-based agents.

27 Aug 2026

Pharma & GLP-1

Samsung Biologics' $1.8 Billion Bid for PolyPeptide: What the Largest Peptide CDMO Acquisition of 2026 Means for the Supply Chain

Samsung Biologics has launched a CHF 1.46 billion all-cash tender offer to acquire Swiss peptide CDMO PolyPeptide Group, with the formal prospectus due by end of August 2026. The deal — the largest peptide manufacturing acquisition of the year — reflects structural demand for GLP-1 API capacity and signals a further consolidation of the CDMO landscape that research-procurement teams should factor into sourcing strategy.

22 Aug 2026

Pharma & GLP-1

Retatrutide Clears Two More Phase 3 Trials — Lilly Targets BLA Filing in Q1 2027

Eli Lilly announced positive topline results from TRIUMPH-2 and TRIUMPH-3 on 23 July 2026, completing the pivotal data package for retatrutide across five Phase 3 studies. The triple-agonist peptide delivered up to 20.8% weight loss in adults with type 2 diabetes and up to 22.6% in those with established cardiovascular disease. A biologics licence application to the FDA is now planned for Q1 2027.

27 Jul 2026

Pharma & GLP-1

ADA 86th Scientific Sessions: What the June 2026 Phase 3 Wave Means for Peptide and GLP-1 Research Procurement

The American Diabetes Association's 86th Scientific Sessions closed in New Orleans on 8 June 2026 with pivotal Phase 3 data for retatrutide, orforglipron, and CagriSema, alongside a formal revision to the ADA Standards of Care that repositions cardiovascular and kidney risk reduction as co-primary treatment goals. The meeting reshapes the near-term clinical and procurement landscape for GLP-1 and next-generation peptide-based therapeutics.

09 Jun 2026

Pharma & GLP-1

Parabilis Medicines Sets Terms for a $476M Nasdaq IPO — What the Helicon Peptide Platform Means for Oncology Research

Parabilis Medicines, formerly FogPharma, set terms this week for a Nasdaq IPO targeting up to $476M, backed by a freshly inked $2.2B milestone deal with Regeneron. Its Helicon stabilised helical peptide platform is designed to reach intracellular targets that have resisted three decades of drug development, with lead candidate zolucatetide posting a 100% disease-control rate in desmoid tumours.

05 Jun 2026

Pharma & GLP-1

Regeneron's $2.3 Billion Bet on Helicon Peptides: What the Parabilis Deal Signals for the Peptide Research Landscape

Regeneron Pharmaceuticals announced a research collaboration with Parabilis Medicines on 18 May 2026, valued at up to $2.32 billion, centred on Helicons — stabilised, cell-penetrant alpha-helical peptides designed to reach intracellular targets that have long resisted conventional drug design. The deal crystallises a strategic shift in how institutional capital now views structurally engineered peptides, with implications extending well beyond oncology.

01 Jun 2026

Pharma & GLP-1

Orforglipron's ATTAIN-MAINTAIN Data Clarifies the Sequential GLP-1 Strategy — and Redraws Research Priorities for Peptide Labs

The ATTAIN-MAINTAIN trial, published in Nature Medicine on 12 May 2026, shows that switching from injectable GLP-1s to oral orforglipron (Foundayo) preserved roughly 75–80% of prior weight loss over 52 weeks. For research-procurement teams, the data crystallises a new sequential treatment paradigm — and raises pointed questions about which peptide and non-peptide reference compounds will be in demand next.

01 Jun 2026

Pharma & GLP-1

Retatrutide's TRIUMPH-1 Phase 3 Data: 28.3% Weight Loss, a Pending NDA, and What It Means for Research Labs

Eli Lilly's triple agonist retatrutide delivered up to 28.3% average body-weight reduction at 80 weeks in the Phase 3 TRIUMPH-1 trial, with a 30.3% result at 104 weeks in a high-BMI sub-group. The data, released 21 May 2026, sets a new efficacy benchmark in the GLP-1 class — and is already intensifying procurement interest in research-grade retatrutide, despite the compound remaining strictly investigational and not compoundable under any current legal pathway.

30 May 2026

Pharma & GLP-1

CHMP Backs Both High-Dose Wegovy HD and Oral Semaglutide for EU Approval — What the Twin Opinions Mean for the Research Landscape

On 22 May 2026, the EMA's Committee for Medicinal Products for Human Use issued positive opinions recommending EU marketing authorisation for both Wegovy HD 7.2 mg in a single-dose pen and the oral Wegovy pill (semaglutide 25 mg). The twin rulings advance semaglutide into new dosing and delivery territory across Europe — with distinct implications for UK regulatory timelines, research procurement, and the purity concerns that continue to surround the grey-market semaglutide supply chain.

24 May 2026